These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20454943)

  • 1. A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation.
    Kim ST; Lee MH; Kim SY; Kim SJ; Kim DH; Jang JH; Kim K; Kim WS; Jung CW
    Int J Hematol; 2010 Jun; 91(5):886-91. PubMed ID: 20454943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study.
    Park SY; Lee SO; Choi SH; Kim YS; Woo JH; Baek S; Sung H; Kim MN; Kim DY; Lee JH; Lee JH; Lee KH; Kim SH
    J Antimicrob Chemother; 2012 Jun; 67(6):1486-92. PubMed ID: 22354954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
    Ju HY; Kang HJ; Hong CR; Lee JW; Kim H; Park KD; Shin HY; Park JD; Choi EH; Lee HJ; Ahn HS
    Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.
    Reusser P; Einsele H; Lee J; Volin L; Rovira M; Engelhard D; Finke J; Cordonnier C; Link H; Ljungman P;
    Blood; 2002 Feb; 99(4):1159-64. PubMed ID: 11830461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
    Takenaka K; Nagafuji K; Takase K; Kamimura T; Mori Y; Ito Y; Nishi Y; Henzan H; Kato K; Harada N; Eto T; Miyamoto T; Teshima T; Akashi K
    Int J Hematol; 2012 Jul; 96(1):94-100. PubMed ID: 22547196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.
    Chawla JS; Ghobadi A; Mosley J; Verkruyse L; Trinkaus K; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Uy GL; Westervelt P; DiPersio JF; Vij R
    Transpl Infect Dis; 2012 Jun; 14(3):259-67. PubMed ID: 22093134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
    Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.
    Park SY; Lee SO; Choi SH; Kim YS; Woo JH; Sung H; Kim MN; Kim DY; Lee JH; Lee JH; Lee KH; Kim SH
    J Clin Microbiol; 2011 Dec; 49(12):4179-84. PubMed ID: 22031700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea.
    Choi SM; Lee DG; Choi JH; Yoo JH; Kim YJ; Park SH; Park SN; Min CK; Lee S; Kim HJ; Kim DW; Lee JW; Min WS; Shin WS; Kim CC
    Int J Hematol; 2005 Jan; 81(1):69-74. PubMed ID: 15717693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
    Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A; de Fabritiis P; Ghisetti V; Allice T; Mirabile M; Gentile G; Locatelli F; Falda M
    Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
    Li L; Wang Y; Yan CH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
    [No Abstract]   [Full Text] [Related]  

  • 16. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
    Boeckh M; Nichols WG; Chemaly RF; Papanicolaou GA; Wingard JR; Xie H; Syrjala KL; Flowers ME; Stevens-Ayers T; Jerome KR; Leisenring W
    Ann Intern Med; 2015 Jan; 162(1):1-10. PubMed ID: 25560711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation.
    Kanda Y; Mineishi S; Saito T; Saito A; Ohnishi M; Niiya H; Chizuka A; Nakai K; Takeuchi T; Matsubara H; Makimoto A; Tanosaki R; Kunitoh H; Tobinai K; Takaue Y
    Transplantation; 2002 Feb; 73(4):568-72. PubMed ID: 11889432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.
    Boeckh M; Gooley TA; Myerson D; Cunningham T; Schoch G; Bowden RA
    Blood; 1996 Nov; 88(10):4063-71. PubMed ID: 8916975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation.
    Jaing TH; Chang TY; Chen SH; Wen YC; Yu TJ; Lee CF; Yang CP; Tsay PK
    Medicine (Baltimore); 2019 Jan; 98(4):e14172. PubMed ID: 30681583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.